« Allarme virus H5N1 anche per l'Italia: "possibili 150 mila morti" | Main | Dr. Martin William's map showing dates of bird flu outbreaks and bird migrations [snag for the Avian Flu Watch group] »

September 15, 2005

GlaxoSmithKline wins $2.8M U.S. avian flu antiviral contract

SAN FRANCISCO (MarketWatch) -- The U.S. Department of Health and Human Services said Thursday that it has awarded GlaxoSmithKline Plc a contract worth $2.8 million to produce 84,300 treatment courses of the antiviral drug zanamivir (Relenza) for treatment of the avian flu. The department said the agreement with GlaxoSmithKline will provide HHS with an initial supply of zanamivir, an antiviral medication that is effective in reducing the severity of symptoms of human seasonal influenza. The H5N1 virus that is circulating in Southeast Asia appears to be sensitive to the antiviral activities of these drugs, the department said. HHS has received the full shipment from this order. HHS also awarded Sanofi-Aventis Group's Sanofi Pasteur unit a contract worth $100 million to produce avian flu vaccine.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Copyright: Copyright 2003, MarketWatch, Inc.

From MarketWatch.com - MarketPulse (feed)
See also links to this feed and more from this feed

Posted by dymaxion at September 15, 2005 04:26 PM

Trackback Pings

TrackBack URL for this entry:


Post a comment

Remember Me?